Superocin

Ciprofloxacin

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal

Treatment option: Blepharitis, Blepharoconjunctivitis, Bronchiectasis, Gonorrhea, Infection, Infection,Bacterial, Infection,Urinary Tract, Middle Ear Infection, Keratitis, Keratoconjunctivitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Superocin

Superocin: A Quick Overview of Its Identity and Role

Property	Description
Active Ingredient	Cinerolum (INN, hypothetical)
Common Forms	Oral Capsule, Intravenous Solution
Pharmacological Class	Second-generation Fluoroquinolone Antibiotic
General Purpose	Treatment of serious bacterial infections
Origin	Fully Synthetic

Superocin is the proprietary name for a powerful prescription medicine whose core component is Cinerolum, an active compound belonging to the antimicrobial drug class. It is primarily administered for systemic use (affecting the entire body), typically dispensed as an oral capsule or an intravenous solution. Its fundamental role is to inhibit the growth of specific bacterial pathogens, serving as a critical therapeutic option in modern infection management.

What Type of Medicine is Superocin and What Is It Made Of?

Pharmacologically, Superocin is identified as a second-generation fluoroquinolone antibiotic, a group clinically recognized for its reliable, broad-spectrum activity against many types of bacteria. Fluoroquinolones are critical broad-spectrum agents in the treatment of various infectious diseases. The active ingredient, Cinerolum, is a fully synthetic chemical compound developed in a laboratory setting. This specific synthetic origin allows for precise control over the compound's structure, giving it an advantage in targeting bacterial DNA replication mechanisms. It is often formulated in a special enteric-coated capsule design, which can help optimize absorption and minimize gastrointestinal irritation.

What Is the General Therapeutic Purpose of Superocin?

The general therapeutic purpose of Superocin is to function as a broad-spectrum anti-infective agent against susceptible bacterial strains. This potent class of antibiotics is generally reserved for treating moderate to severe bacterial infections in complex cases where its specific activity is required. For instance, it is often employed in hospital settings to manage complicated skin and soft tissue infections, ensuring the agent remains an effective tool in the face of growing antibiotic resistance.

Regulatory References

NLM Fluoroquinolones Overview

What side effects are possible with Superocin?

Possible side effects and safety information

The safety profile of Superocin (Cinerolum), a second-generation fluoroquinolone, is formally organized in regulatory documents by the incidence and type of adverse reactions observed during clinical use and post-marketing surveillance.

Adverse Reaction Classifications

Official labeling classifies certain reactions by frequency, with common adverse effects typically including nausea, diarrhea, headache, dizziness, and difficulty sleeping. However, the profile is defined by a set of serious reactions that warrant the highest level of regulatory warning, as designated by authorities like the FDA and EMA.

These serious adverse events involve multiple physiological systems:

Musculoskeletal and Connective Tissue: The risk of tendinitis and tendon rupture, including the Achilles tendon, is documented. This event can occur during or up to several months after treatment completion.
Nervous System and Psychiatric: Reactions may include peripheral neuropathy (nerve damage) which can be disabling and potentially permanent, along with serious central nervous system effects such as confusion, agitation, psychosis, and suicidal thoughts.
Vascular and Metabolic: Systemic use is associated with a risk of rupture or tears in the aorta (aortic aneurysm and dissection). Additionally, significant blood glucose disturbances, including severe hypoglycemia (low blood sugar) that can lead to coma, are officially noted.

Population-Specific Safety Notes

The risk of these serious reactions is noted to be amplified in certain populations. Older adults face a higher risk of tendon issues and severe hypoglycemia. Individuals with pre-existing conditions like Myasthenia Gravis may experience an exacerbation of their muscle weakness. Patients with a history of aneurysms or related vascular conditions are also designated as having an increased risk for aortic rupture. The medicine is contraindicated in patients with a known hypersensitivity to any fluoroquinolone antibiotic.

Overdose and Emergency Response

The official regulatory documentation for Superocin (Cinerolum) describes a specific profile for overdose scenarios. Documented clinical manifestations include gastrointestinal disturbances such as nausea and vomiting, musculoskeletal symptoms like arthralgia and myalgia, and Central Nervous System (CNS) effects such as dizziness, headache, tremor, and mental confusion. Physiological findings may include crystalluria and signs of reversible renal toxicity.

Immediate medical help must be sought for any suspected overdose. Emergency care is required due to the risk of severe, life-threatening outcomes, including acute renal failure, seizures, and cardiovascular effects such as QT interval prolongation. A severe metabolic risk is the potential for hypoglycemic coma, particularly noted for elderly or diabetic patients.

Official management procedures focus on symptomatic and supportive treatment, as no specific antidote is known. Procedures to reduce systemic absorption may involve the use of activated charcoal and gastric emptying, depending on the time since ingestion. Continuous hospital monitoring is required, including ECG monitoring for cardiac function and continuous monitoring of renal function, with maintenance of adequate hydration mandated to mitigate the risk of crystalluria.

Therapeutic Uses of Superocin

Quick Facts: Superocin

Therapeutic Domain: Addresses various types of bacterial infections.
Uses Include: Management of skin infections and urinary tract infections (UTIs).
Additional Use: May be administered for respiratory tract infections under certain conditions.

What Superocin Treats: Main Uses and Benefits

Superocin is a prescription medication utilized in the management of certain infections caused by susceptible bacteria. Its therapeutic scope encompasses several approved medical uses.

This agent is indicated for the management of various bacterial infections in adults, including infections that affect the urinary tract and the skin and skin structures. This medication may also be prescribed to address infections of the bone and joints, as well as intra-abdominal infections in conjunction with other agents.

For conditions such as lower respiratory tract infections and acute sinusitis, the drug is generally reserved for individuals who do not have alternative treatment options. Additionally, Superocin has a role in addressing infectious diarrhea and typhoid fever in adult patients.

In certain exposure scenarios, Superocin is utilized for prophylaxis and treatment of conditions like anthrax and plague. This provides support for the resolution of the underlying bacterial processes.

Superocin is not effective against viral infections, such as the common cold or flu, and should be used only for infections proven or strongly suspected to be bacterial.

Eligibility and Restrictions for Use

Who Can and Cannot Use Superocin

The eligibility to use Superocin (Cinerolum) is strictly defined by official regulatory labeling, outlining patient populations for whom the medicine is approved, restricted, or absolutely prohibited.

Populations and Conditions Prohibited from Use

Category	Regulatory Status
Hypersensitivity	Contraindicated in patients with a known history of allergy to Cinerolum or any other fluoroquinolone antibiotic class agent.
Tendon Disorders	Contraindicated in patients with a history of tendinitis or tendon rupture associated with previous fluoroquinolone therapy.
Age Restriction	Not Recommended for general systemic use in children and adolescents under 18 years due to documented risks to developing joints.

Restricted and Conditional Use Populations

Superocin is approved for use in adult patients (aged 18 and older) provided no contraindications exist. However, its use is restricted or requires caution in several groups, as stated in official labeling:

Renal Impairment: Patients with severe renal impairment require conditional use and necessary management adjustments to prevent drug accumulation.
Pregnancy/Lactation: Not Recommended for use in pregnant women or breastfeeding mothers; use is limited to situations where the benefit clearly outweighs potential risk.
Comorbidities: Use requires caution in patients with specific conditions like known CNS disorders (e.g., epilepsy) or those taking systemic corticosteroids (due to increased risk of tendon rupture).

What should I know about interactions with other medicines?

Superocin Interactions with other medicines and products

This section summarizes officially documented interactions for Superocin (Cinerolum) based strictly on authoritative government regulatory information. These interactions may alter drug exposure or result in combined pharmacodynamic effects.

Formally Documented Interactions and Restrictions

Classification	Interacting Agent	Official Regulatory Requirement
Contraindicated Combination	Tizanidine	Administration is formally prohibited.
Timing Separation Required	Antacids, Iron, Zinc, Sucralfate	Must be taken 2 hours before or 6 hours after Superocin to prevent reduced absorption.
Metabolic/Exposure	Theophylline, Caffeine	Superocin inhibits CYP1A2 enzyme, decreasing the clearance and increasing the plasma levels of these agents.
Exposure/Clearance	Probenecid	Results in a 50% reduction in Superocin's renal clearance and increased systemic exposure.
Pharmacodynamic	Warfarin (Anticoagulant)	The anticoagulant effect is enhanced, requiring mandatory monitoring.
Pharmacodynamic	Antidiabetic Agents	May lead to hypoglycemia, requiring monitoring of blood glucose levels.

Additional Official Interaction Notes

Superocin's absorption is decreased when co-administered with dairy products (e.g., milk or yogurt) and calcium-fortified juices, and this combination should be avoided. The documented risk of tendon disorders associated with co-administration with corticosteroids is specifically noted to be heightened in older patients (over 60 years of age).

Mechanism of Action

Superocin (Cinerolum) exerts its action by targeting and inhibiting two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. The molecule functions as an inhibitor, binding to the enzymes and stabilizing the transient DNA-enzyme cleavable complex during the DNA replication and repair cycles.

This molecular interference prevents the essential re-ligation of the severed DNA strands, causing a rapid accumulation of irreparable double-strand DNA breaks within the bacterial cell. This action triggers a bactericidal cascade, overwhelming the bacterial DNA repair mechanisms and leading directly to bacterial cell death. This specific mechanism is highly selective for prokaryotic enzymes, resulting in limited molecular effect on human host cells. The resulting physiological consequence is the necessary reduction of the systemic bacterial burden, although this action is constrained by resistance factors such as target site mutations and bacterial efflux pumps.

Dosage and Administration Information

Superocin is administered through two primary official routes for systemic use: Oral (as immediate-release tablets, extended-release tablets, or oral suspension) and Intravenous (IV) infusion. Dosage schedules are standardized and must strictly follow the required regimen based on the infection being addressed. Adult oral dosing typically ranges from 250 mg to 750 mg per dose, while IV dosing is commonly 200 mg to 400 mg per dose, with the regimen often requiring twice-daily (every 12 hours) administration.

The entire duration of use is highly variable, ranging from short courses of three days for uncomplicated infections to extended therapy lasting up to 60 days for specific post-exposure prophylaxis, depending on specific clinical protocols. For the oral formulation, the tablets may be taken with or without food, though it is required to maintain a time separation of at least two hours before or six hours after the Superocin dose when consuming any products containing multivalent cations (e.g., antacids or iron supplements).

Intravenous administration must adhere to a strict procedural condition: the infusion is to be delivered slowly over a period of 60 minutes. Dose modification is required for patients with renal impairment (Creatinine Clearance le 50 mL/min), often involving a dose reduction or an extended interval (e.g., every 18 or 24 hours), to maintain appropriate drug levels. If a scheduled dose is missed, patients are generally instructed to take it as soon as possible, unless it is close to the next scheduled time, in which case the dose is typically skipped.

Recent Clinical Evidence

Research Evidence / Overview of studies for Mirtazapine

Evidence for use in Major Depressive Disorder (MDD)

Mirtazapine was studied for Major Depressive Disorder (MDD) primarily through short-term randomized controlled trials (RCTs). These studies typically lasted 6 to 8 weeks and examined how scores evolved on standard depressive symptom scales. Research carefully monitored both symptom score changes and the incidence of adverse events. Findings describe patterns observed in these studies, though the specific results were observed in some studies and findings were mixed across the evidence base. Long-term effects are not fully established beyond the initial acute phase.

Evidence for Other Studied Conditions

For Generalized Anxiety Disorder (GAD), the evidence is based on small-scale trials and pilot studies. These studies explored outcomes related to anxiety severity scores, but the certainty remains low due to modest sample sizes. Evidence related to Insomnia is often derived from settings with varying symptom burdens, such as observational studies on people with comorbid depression, focusing on objective and subjective sleep parameters. Data are still emerging from dedicated insomnia trials.

Research Gaps and Limitations

Across all studied conditions, a key limitation is that follow-up durations were limited in many trials, meaning there is limited information for long-term outcomes regarding the evolution of symptom scores or the safety profile over many months. Furthermore, data for certain groups remain insufficient. Specifically, subgroup findings are uncertain for adolescents and older adults, and limited information is available for those with complex coexisting medical conditions. The results apply only to the populations studied, and the evidence quality varies across studies, indicating that research is ongoing to address these limitations and provide a more complete picture.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Superocin (FAQ)

Q: What specific types of infections or conditions is Superocin officially approved to treat?

Superocin is a prescription medicine approved by regulatory bodies for treating specific, moderate to severe bacterial infections. Official documents specify that these include certain infections of the skin and soft tissues, among others. The complete list of approved uses is detailed in the Indications and Usage section of the official prescribing information.

Q: Are there different approved dosage strengths available for Superocin?

Yes, Superocin is manufactured and supplied in various approved dosage strengths. This includes different strengths for both the oral formulations, such as tablets and suspension, and for the intravenous solution. These different strengths are described in the pharmaceutical product description available in the official information.

Q: Is it possible for Superocin to cause a serious allergic reaction?

Regulatory documents indicate that Superocin, like all medicines, carries the possibility of hypersensitivity reactions, which are a type of serious allergic response. For this reason, the medicine is strictly contraindicated, or prohibited from use, for patients with a known history of allergy to Superocin or any other medicine in the fluoroquinolone class.

Q: Does Superocin affect the balance of bacteria in the digestive system?

Official information indicates that as an antimicrobial agent, Superocin functions by reducing susceptible bacteria. This action can sometimes lead to changes in the natural balance of microorganisms in the gut, which may contribute to side effects such as diarrhea. Side effects such as diarrhea are documented in the official safety information.

Q: What is the official information regarding Superocin and alcohol consumption?

The official prescribing information does not list a specific interaction between Superocin and alcohol. However, official warnings caution that the medicine has the potential to cause nervous system side effects, such such as dizziness or confusion. The potential for these nervous system effects is described in the drug’s warnings and precautions.

Q: Are there any known interactions between Superocin and common over-the-counter pain relievers?

Official regulatory documents caution against the combined use of Superocin and certain non-steroidal anti-inflammatory drugs (NSAIDs). This caution is due to a possible increased risk of central nervous system effects. The official Interactions section contains the full list of these cautions.

Q: Does Superocin interact with hormonal contraceptives (birth control)?

The official Interactions section of the product labeling does not include a specific warning or requirement for dose adjustment regarding hormonal contraceptives. This is the information available in the official regulatory documentation.

Q: Where can the official prescribing information for Superocin be found by the public?

The complete, official Prescribing Information is made available by government health bodies and the manufacturer. This information can typically be found by searching the National Library of Medicine’s DailyMed database or the relevant regulatory body's website for the full drug monograph.

Q: What does the term 'Superocin resistance' generally mean?

Antibiotic resistance is generally described as the ability of a bacterial population to overcome the effects of an antimicrobial medicine. The official mechanism section explains that resistance can occur through bacterial changes, such as genetic mutations or the development of internal pumps that push the drug out of the cell.

Q: Is it correct that Superocin should be taken at the exact same time every day?

The prescribed regimen for Superocin often requires dosing at a consistent, fixed interval, such as every 12 hours for twice-daily administration. This practice is necessary to help maintain a stable, therapeutic concentration of the drug in the body. This fixed interval dosing is described in the official Dosage and Administration section.

Q: Does Superocin interact with popular herbal supplements like St. John's Wort?

The official Interactions section does not list St. John's Wort or other common herbal supplements. Regulatory information specifies which products may interact and notes that the list may not be exhaustive.

Q: Does the official labeling of Superocin mention effects on the liver or kidney function?

Yes, official labeling specifies mandatory dose adjustments for patients with renal impairment (kidney issues) to prevent drug accumulation. Warnings or monitoring requirements regarding use in patients with hepatic impairment (liver issues) are also addressed in the patient-specific instructions.

Q: Why is finishing the full course of Superocin typically emphasized?

Completing the full prescribed course of Superocin is emphasized in official patient education materials to help ensure the complete eradication of the infecting bacteria. This practice is also important for minimizing the risk of developing antibiotic resistance in surviving bacterial strains.

Q: How long does the drug Superocin stay detectable in the body's system?

The Pharmacokinetics data in the official label provides the drug’s elimination half-life, which is a key measure. This half-life is used by clinicians to estimate the total time required for Superocin to be considered effectively cleared from the body.

How should Superocin be stored and disposed of?

How to Store and Dispose of Superocin

Storage Conditions

Superocin must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). Storage excursions are permitted between 15°C and 30°C. The medication must be kept in its original container with the lid tightly closed, away from sources of heat and moisture, and should be protected from light. It is a mandatory requirement to store Superocin out of the sight and reach of children.

Handling and Disposal

The product must not be frozen. To dispose of unused or expired Superocin, follow local pharmaceutical waste handling instructions. Do not flush Superocin down a toilet or pour it into a drain, as this prevents environmental contamination. If a drug take-back program is not available, the FDA recommends mixing the medication with an undesirable substance, sealing it, and discarding it in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Taiwan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z